Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Bausch & Lomb Incorporated
EIR
•Bausch & Lomb Incorporated•February 25, 2016

Bausch & Lomb Incorporated – FDA EIR, Feb 25, 2016

Record Details

An FDA inspection of Bausch & Lomb, Inc. in Tampa, FL, was conducted from February 8 to February 25, 2016. This inspection served as an abbreviated cGMP review, a pre-approval inspection for NDA 207795 (Latanoprostene Bunod 0.024% Topical Ophthalmic Solution), and a follow-up on unapproved drugs, adhering to drug manufacturing and pre-approval inspection guidelines. The inspection identified significant concerns, resulting in an FDA-483 with several observations. Key issues included incomplete nonconformance investigations for particulate matter and environmental monitoring, lacking scientific justification. Environmental monitoring samples were improperly taken under non-dynamic conditions, and hold time studies for cleaned equipment were deemed inadequate. Furthermore, in-process controls were not adequately selected to ensure production is consistently controlled. A systemic particulate issue was noted on aseptic filling lines, suggesting deficiencies in facility design, equipment, maintenance, and airflow controls. The firm's quality system was found ineffective in identifying, resolving, and preventing these quality issues. Previous inspection findings, such as non-compliance with supplier audit procedures, remained unaddressed and contributed to the current particulate findings. As a result, a withhold recommendation was issued for NDA 207795 due to these unacceptable cGMP conditions and an ineffective quality system. Bausch & Lomb's management committed to addressing the observations to achieve sufficient control over manufacturing operations and prevent future quality issues.

Company
Bausch & Lomb Incorporated
Inspection date
February 25, 2016
Product type
drugs
Office
Center for Drug Evaluation and Research
People
  • Michael H. Tollon (Approval Manager)
  • Denise M. Digiulio (Federal Agencies)
View Company Profile

ID · 069f4152-87c1-4fe6-8159-216b4dda877f

Other documents for Bausch & Lomb Incorporated
  • 483 - 2026-03-20March 20, 2026
  • 483 - 2017-05-26May 26, 2017
  • EIR - 2017-05-26May 26, 2017
  • 483 - 2016-02-25February 25, 2016
  • WARNING_LETTER - 2012-10-02October 2, 2012

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Bausch & Lomb Incorporated
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.